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During the last decades, solid supported chemistry methods have played a significant 
role in chemical biology and especially in drug discovery. Solid-phase synthesis (SPS) 
is the method of choice for chemical synthesis of biologically active oligomers like 
peptides, DNA, RNA, and PNA. It is also well suited for the production of chemical 
compound libraries. In drug discovery, large masses of chemical compounds contained 
in these libraries have been tested against biological targets to find novel active com-
pounds for further development. Although currently about 100 million compounds of 
the hundreds of billions of possibly active organic small molecules have been synthe-
tized, it still seems to be difficult to develop new small molecule drugs.1,2 Moreover, it 
seems that the chemical space the synthesized molecular libraries cover is relatively 
small, as is the number of utilized molecular frameworks.3 With considerations akin to 
above in mind, we decided to put an effort to develop new methods for library synthe-
sis of compounds that could be of value for medicinal chemistry. This thesis summa-
rizes some of that work. 
1.1 Solid‐Phase	Synthesis		
By writing a notebook entry “A New Approach to the Continuous, Stepwise Synthesis 
of Peptides” in 1959 Bruce Merrifield started a development that revolutionized the 
field of synthetic organic chemistry.4 At first, the concept of solid-phase synthesis gen-
erated strong resistance among the scientific community. In traditional synthetic organ-
ic chemistry, isolation and characterization of reaction intermediates were needed as 
evidence supporting the chemical structure of the product. Isolation of the intermedi-
ates was often required for practical reasons as well: accumulation of the side products 
from consecutive synthesis steps could lead to a complex product mixture hard to frac-
tionate into pure products. By contrast, in solid-phase chemistry a large excess of rea-
gents are often used to force the reactions as close to completion as possible. In addi-
tion, multiple reaction steps are performed successively with only a simple washing off 
of excess reagents from the solid support between the steps. As a result, good planning 
and optimization of the synthesis route is necessary and furthermore, the products 
cleaved from the solid support require careful purification and characterization. The 
breakthrough of SPS would not have been feasible without concomitant advances in 
both purification techniques and analytic methods, such as HPLC, capillary electropho-
resis, mass spectrometry, NMR spectroscopy, and automated amino acid analysis. On-
ly a decade after the preparation of the first compound, namely tetrapeptide Leu-Ala-
Gly-Val, produced on a solid-phase,5 and after several improvements and extensions, 
the SPS method started to gain general acceptance. The subsequent years brought 
about a large variety of linkers, protecting groups, coupling reagents, solid supports, 
peptide synthesizers, as well as extensions to other areas of organic chemistry, for ex-
ample to synthesis of depsipeptides6, polyamides7, oligonucleotides8–11, oligosaccha-
rides12–14, peptide nucleic acids15,16, and to solid-phase organic synthesis (SPOS)17–21 
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Moreover, the SPS methodology started the era of combinatorial chemistry in 1980s22–
28. The SPS method is scalable from detection limit to metric ton scale industrial appli-
cations. For example, there are currently about thirty approved peptide pharmaceuticals 
that are manufactured in industrial scale by solid-phase peptide chemistry (SPPS).29 
1.2 Advantages	and	Disadvantages	of	Using	Insoluble	Polymer	Support	
The idea of the SPS is simple: the substrate is attached to a polymer support, the in-
tended chemical reaction is carried out and the excess reagents are washed off. This 
reaction-wash cycle is repeated until the synthesis is ready and the product is cleaved 
from the support (Scheme 1). 
Anchoring of the substrate to an insoluble matrix has several advantages.30 The most 
obvious and important advantage is that reaction work-up is simplified because excess 
reagents and soluble by-products can be removed by resin washing and filtration. Hence, 
it may be possible to avoid exposure of the reaction products to water (extraction) or to 
avoid chromatographic purification of the intermediate products. There is usually no 
need to dry the resin between washing and reaction steps which increases the speed of 
the synthesis. The ease of separation allows one to use a large excess of reagents, in case 
this leads to better reaction yields. Moreover, the process is highly applicable to automa-
tion. This is important especially for the industrial and combinatorial chemistry applica-
tions. SPS is particularly suitable for synthesis of oligomeric and polymeric compounds 
where automation of repetitive synthesis steps in a sealed environment brings about 
speed, reproducibility and higher yields compared to manual laboratory work.  
 
Scheme 1. The main principle of solid-phase chemistry. 
In many applications, especially on using polymer-supported catalysts, reagents and 
scavengers (vide infra), it is reasonable to recover, regenerate and reuse the solid-
support.20 Hence, polymers with complex functionalities that are economic or ecologic 
to use compared to their low-molecular weight analogues can be designed. A further 
advantage is that polymer bound functionalities, which would be significantly toxic or 
noxious as low molecular weight compounds, show reduced toxicity and are odourless 
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a) A truncated peptide is a peptide which becomes unavailable for reaction at some stage in the
synthesis and does not add any further amino acids. A deletion sequence is a truncated peptide
which resumes growth at some later stage in the synthesis. 
making handling of the material easier. The solid-supported chemistry can also be 
adapted to flow systems for both industrial and laboratory scale applications.31  
Reactions are heterogeneous when performed on insoluble polymer matrix. 32  This 
leads to differences between reactions on a solid-support and in solution. The main 
types of differences are: effects resulting from the need for the soluble reagent to gain 
access to the supported reactants (i.e. diffusion), microenvironmental effects, and site–
site interactions or site-isolation. The first may result in significant size selectivity or 
slower reactions, the second difference in polarity of the microenvironment of the sub-
strate compared to the bulk of solvent, and the third either higher or lower intraresin 
reactivity33. The heterogeneity of the solid-supported reaction system is most often 
seen as a disadvantage although, for example, site-isolation has been successfully uti-
lized in synthesis of cyclic peptides already during the early days of SPPS.34  
It is crucial that reactions on solid-supported substrates proceed in very high yields 
with few side reactions because purification of intermediates is not possible. Formation 
of side-products may lead to a complex product mixture which severely complicates 
the purification of the desired products. For example, synthesis of a 40 amino acid 
peptide with a 99% average yield per deprotection-coupling cycle gives theoretically 
67% correct product (Table 1.). The rest of the product mixture consists of diverse 
truncated and deletion sequencesa or false products that have suffered side-reactions. 
These side-products may be very similar to the desired product and may possess simi-
lar chromatographic properties as well, making the purification difficult. The yield 
limitation restricts the size of the oligomers that are feasibly synthesized by stepwise 
coupling reactions. The practical limit for peptide sequence length is currently between 
50 to 100 amino acid residues. For shorter syntheses, lower yields per step may pro-
duce acceptable results if the end product is sufficiently pure or easy to purify. 
Table 1. Yields of final product in a multistep synthesis as a function of number of 
steps and yield per step. 
 Number of steps 
Yield per step 2 3 4 5 10 20 30 40  50 
99% 98% 97% 96% 95% 90% 82% 74% 67%  61% 
95% 90% 86% 81% 77% 60% 36% 21% 13%  8% 
90% 81% 73% 66% 59% 35% 12% 4% 1%  1% 
85% 72% 61% 52% 44% 20% 4% 1% 0%  0% 
80% 64% 51% 41% 33% 11% 1% 0% 0%  0% 
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Owing to the requirement of high yield and clean reactions, every synthesis step has to 
be carefully optimized. This can be quite a demanding and time consuming process. 
Optimization is laborious for solid-supported substrates in particular, because monitor-
ing of the reaction progress and outcome is often impossible without cleaving a sample 
from the resin and analysing it. Czarnik has summarized some of the issues that one 
needs to take into account when planning a solid-phase organic synthesis, the main 
point being that a gel type solid-support is like a solvent.35 Thus, the swollen resin 
together with the added solvent is the actual reaction solvent, although very viscose 
one.36 Naturally, the selected solvent has an influence on reaction outcome and the 
resin should be chosen bearing this in mind.37,38 The commonly used microporous res-
ins need to swell in the reaction solvent for the reagents to gain access to the supported 
reactant or reagent.39 In addition to the above mentioned, different batches of resins 
with similar specifications may behave differently in solid-phase synthesis.40 Although 
the situation is better than 20 years ago when Pugh and co-workers reported41 that the 
indicated cross-linking, mesh size range, and substitution are frequently inaccurate on 
commercial resins, the problem still exists40. Also age of the resin influences its per-
formance.35,42 The loading of a resin may decrease over the time since the reactive 
groups are not inert to storage and handling. Resins may contain entrapped impurities 
that can hamper the synthesis or if not reacting, they at least bias the determination of 
the yield and reaction monitoring.43 For these reasons, it is advisable to optimize the 
reaction conditions and carry out the actual synthesis with the same batch of resin, 
prewash it well before use, and determine its swelling capacity as a simple measure of 
resin performance.40  
1.3 Polymer‐Assisted	Solution‐Phase	Synthesis	
In parallel with the solid-phase synthesis, evolved the chemistry of polymer-supported 
reagents, catalysts, and scavengers (PS-RCS). 44 , 45  The origins of the polymer-
supported catalysts actually trace back to the development of ion-exchange resins in 
forties and fifties so that several reviews of the ion-exchange catalysis already existed 
by the advent of SPS46,47. PS-RCS methods have attracted only modest interest until 
last ten or fifteen years. The need to simplify work-up and reaction procedures in paral-
lel synthesis and high-throughput screening has changed the situation. After initial 
popularity of SPOS in combinatorial synthesis, many chemists have preferred solution 
synthesis as a method of choice for preparation of combinatorial libraries.48 –50 The 
reasons include time consuming and expensive method development, slower reactions 
on solid support, low quantities of products produced, difficulties in reaction monitor-
ing, and a need for an attachment point to the support.51 On the other hand, high 
throughput parallel synthesis in solution has one major disadvantage, namely purifica-
tion. Many solutions to address the problem have appeared.52 –54 One solution has been 
to use in combination solution-phase synthesis and purification techniques that utilize 
solid-support. This polymer-assisted solution-phase (PASP) synthesis method can be 
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divided into two main approaches: PS-RCS (Scheme 2a-c) and catch-and-release ap-
proaches (Scheme 2d).55 In case of polymer-supported catalysts (Scheme 2 a), the 
catalyst is separated from the reaction mixture and after regeneration reused. If a rea-
gent is bound to the support, the reaction product is purified by filtering off the bound 
by-products and excess reagent (Scheme 2 b). Scavenger resins can be used to pick out 
a reaction component after reaction to facilitate the purification (Scheme 2 c). For ex-
ample, aminomethylated polystyrene can be used to remove electrophiles like acid 
chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates.56 A similar method is 
solid-phase extraction (SPE). While scavenger resins form a covalent bond with the 
impurities, SPE is based on noncovalent interactions. In catch-and-release or resin 
capture approach (Scheme 2 d), the product is purified by fishing it out from the reac-
tion mixture with a polymer support and after filtration released to solution. In a varia-
tion of this method, a reactant is attached to the resin via activated bond which is then 
cleaved by conjugate reactant.  
 
Scheme 2. The principle of using polymer-supported catalysts (a), reagents (b), scav-
engers (c), and resin capture method (d). 
There are some advantages in PASP synthesis compared to SPOS in library produc-
tion.53 Firstly, in PS-RCS methods, synthesis is two steps shorter because the substrate 
is not attached and detached from the support. For the same reason, there is no need for 
a functionality to attach the substrate orthogonally57 to the polymer either. Secondly, 
the utilized polymer can be chosen or tailored for the best reactivity for each step in 
question unlike in SPOS where the substrate remains bound to chosen polymer through 
the whole synthesis. Thirdly, because substrate and products are in solution, reaction 
can be monitored by traditional methods.31 One important difference is that it is possi-
ble to purify products from synthesis steps which do not proceed cleanly to comple-
tion. Also, the use of convergent synthesis strategies is easier in PASP synthesis. Final-
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ly, it is possible to perform simultaneously successive reactions in same solution by 
using a mixture of solid-supports.58 –60 Limitations of PASP synthesis include high cost 
and in some cases rapid deterioration of product quality in multistep synthesis.61 Addi-
tionally many of the problems associated with heterogeneous reaction system may 
apply also for PASP methods, that is, slow diffusion, microenvironmental effects and 
intraresin reactivity.62 A more thorough comparison between solution- and solid-phase 
combinatorial chemistry can be found in Carmen Baldino’s perspective article61. It can 
be concluded that both methods are suitable for combinatorial library production and 
that the method or their combination should be chosen by application and available 
resources. For the synthesis of oligo- or polymeric peptides and nucleic acids SPS re-
mains the method of choice in most cases. 
1.4 Resins	for	Solid‐Phase	Organic	Synthesis	
There are two types of solid supports: gel type microporous resins and macroporous 
resins. In addition there are soluble polymer supports63–66 which are not covered in this 
book. While there are numerous different solid supports developed for SPOS, it is be-
yond the scope of this thesis to review them thoroughly. The most commonly used 
resins in SPOS have been (examples in parentheses) polystyrene cross-linked with 
divinylbenzene5 (DVB-PS) or 1,4-bis(vinylphenoxy)butane67 (JandaJel), polystyrene 
poly(ethylene glycol) graft copolymers68,69 (PEG-PS, Tentagel or TG, Argogel, No-
vagel), polyacrylamides 70 , 71  (Pepsyn), polyacrylamides cross-linked with PEG 72 
(PEGA), PEG cross-linked ethoxylate acrylate resin73 (CLEAR), cross-linked PEG74 
(ChemMatrix), and Silica75,76 (controlled pore glass, i.e. CPG).63,77 The support materi-
al is mostly in bead form in either 100–200 mesh (75–152 µm) or 200–400 mesh (37–
75 µm) range. In some cases (e.g. CPG and Pepsyn K) the shape of the particles is 
irregular. In addition to small particular form, the support can be grafted on variety of 
surfaces, for example on films, membranes, polyethylene pins, crowns or discs, or 
glass.78 Cotton and cellulose has also been used as a solid support. Some properties of 
the common support types are summarized in Table 2 and structures in Figure 1. 
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0.3 – 4.0 Widely used for peptide synthesis and SPOS in general. 
Good chemical stability. May suffer from osmotic shock. 
JandaJel 0.45 – 1.2 Because of more flexible cross-linker, swells better than 
DVB-PS. Reactions are more homogenous on JandaJel 
which may lead to better rates and yields in SPOS. 
Tentagel 0.1 – 0.6 Prepared by polymerization of ethylene oxide on PS. 
Useful for synthesis of oligomeric biomolecules.  
Novagel 0.6 – 0.8 Like TG but made by partial derivatization of AM-PS 
with Methyl-PEG2000-p-nitrophenylcarbonate. Unlike in 
TG where linker is attached to the end of PEG chains,
the linker is attached to PS core. Has higher loading than 
TG. 
PEGA 0.2 – 0.4 Hydrophilic resin for SPPS and SPOS. PEGA swells
extensively and is permeable to macromolecules. 
CLEAR 0.2 – 0.6 Highly cross-linked PEG with no PS core. A very polar 
resin with good swelling characteristics. For synthesis of 
difficult peptide sequences. 
ChemMatrix 0.3 – 1.2 A PEG resin with good physical and chemical proper-
ties. It has higher loadings than other PEG resins. Espe-
cially good for synthesis of difficult peptide sequences. 
CPG 0.02 – 0.05 
(0.44) 
Mostly used in oligonucleotide synthesis. Low loading 
with or without spacers. Partial negative charge on sur-
face even with coating. Unsuitable for reactions with
fluorides or highly corrosive chemicals. 
 
1.4.1 Microporous	Resins	
Gel type resins are polymers that are lightly cross-linked (typically 0.5–2% divi-
nylbenzene for polystyrene). In dry state, their amorphous polymer chain network is 
collapsed and the polymer chains are in molecular contact with each other resulting in 
a very low surface area.39 Diffusion of any molecule through this glass state is very 
slow. When polymer gets into contact with a solvent that has similar polarity as the 
polymer, it starts to imbibe the solvent and swell. Individual polymer chains migrate 
further apart within the limits of cross-links and entanglements while the solvent fills 
the swelling bead from the outside inwards. Degree of cross-linking determines how 
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much a polymer can swell. Low level of cross-linker (under 1%) yields exceedingly 
swellable mechanically weak resin networks, while highly cross-linked polymers, 
though mechanically stronger, do not swell much even in good solvents (except 
CLEAR resin). In microporous resins, functional groups are evenly distributed through 
the polymer network, which means that they are mostly located inside the resin bead.79 
Therefore good swelling is crucial for the reagents to gain access to the supported reac-
tant or reagent. There exists no universal polarity scale that would accurately interpret 
all solvent effects80 and thus performance of a solvent has to be assessed experimental-
ly. Experimental swelling properties of solid supports in different solvents are listed in 
literature.81 –83 Table 3 represents swelling of six resins in eleven common solvents that 
are in decreasing polarity order.  
Table 3. Swelling of six resins in eleven solvents (volume in mL/g). Dark grey colour 
indicates poor swelling, light grey moderate, and white good swelling. For Tentagel 
lower limits were used because of lower overall swelling and loading resulting from 
the PEG substitution. 










TFA 2 4 4.5 6.4 16.2 e 
water 1.6 2.2 1.0 3.6 11.0 16.0 
Methanol 1.6 1.2 5.0 3.6 9.0 13.0 
MeCN 2.0 2.8 2.0 4.0 6.2 e 
DMSO 4.2 2.2 8.3 3.8 8.0 e 
DMF 5.2 5.6 6.5 4.4 8.5 11.0 
NMP 6.4 7.2 8.6 4.4 9.0 – 
DCM 5.4 7.6 6.0 5.6 11.5 13.0 
Pyridine 6.0 7.0 4.8 4.6 – – 
Et2O 2.8 3.4 2.0 2.0 – 
f 
heptane 1.6 1.6 2.0 1.6 – – 
a) Solvents are in decreasing polarity order by Dimroth–Reichardt ET(30) parameter, 
except TFA, for which ET(30) parameter cannot be determined. 
b) PS-Wang = Wang polystyrene (1% DVB, 0.6 mmol/g), MBHA-PS = methyl-
benzhydrylamine polystyrene (2% DVB, 0.8 mmol/g), TG S RAM = Rink amide 
Tentagel (1% DVB, 0.3 mmol/g)82 
c) AM-CM = Aminomethyl ChemMatrix (0.4 mmol/g)84 
d) PEGA800 = Amino substituted PEGA (molecular weight of PEG chains is 800 
g/mol, 0.4 mmol/g)85 
e) Similar swelling as in DMF or DCM86 
f) No swelling87 
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Figure 1. Structures of some common resins. 
In addition to the solvent, the support bound molecules and their possible ionization 
have a major influence on swelling behaviour and reaction kinetics. For example, 
chloromethylated polystyrene resin swells well in toluene and not at all in water. Its 
reaction with trimethylamine to form benzyltrimethylammonium chloride residues 
yields a resin that is collapsed in toluene while swollen in water.39 Hence, in a multi-
step synthesis on a support, swelling behaviour may vary considerably. The extent of 
swelling can also markedly increase during the synthesis which has to be taken into 
account when choosing the synthesis vessel. To study this effect in SPPS, Sarin, Kent, 
and Merrifield synthesized a 60 residue long peptide on aminomethyl copoly(styrene–
1% divinylbenzene) with 0.95 mmol/g initial loading.88 After the synthesis, peptide 
content of the resin was 81% by weight. The volume of dry resin beads increased five-
fold and beads swelled in DMF over 26-fold compared to dry unloaded beads. While 
the resin initially imbibed 2.3 mL DMF/g resin, the peptide resin imbibed 21.3 mL 
respectively. The results indicate that against common sense, the volume available for 
growing peptide chains increased inside the swollen bead as the synthesis progressed 
because of the mutual solubilizing effect of the resin and the peptide. Then again, in 
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case of increased holdup volume, either the concentration of reagents decreases or 
increased molar amounts of reagents are required if the concentration is kept high for 
optimum reaction rates. More solvent is also needed for efficient washing of the resin. 
1.4.2 Macroporous	Resins	
Macroporous resins are highly cross-linked (>8% cross-linker) and they have a perma-
nent porous structure and functionalization on the surface of a bead.39,89 They don’t 
swell markedly in any solvent making the choice of solvent less critical for functionali-
ty of the support. Non-swelling supports with good loading and accessibility allow 
high volumetric yield and lower solvent consumption which benefits large scale auto-
mated SPOS.90 Because of the rigid open pore structure, diffusion of reagents to reac-
tion sites is rapid. Likewise, removal of excess reagents and by-products in washing 
steps is quick. Also removal of the solvent from the resin is fast.78 Macroporous resins 
are resistant to osmotic shock.39 They have been used especially as ion-exchange resins 
which was their first application.91,92 Other applications include solid-phase extraction, 
scavenger resins, and heterogeneous catalysis.93 Macroporous resins have gained lim-
ited popularity in SPOS or SPPS with the exception of oligonucleotide synthesis. A 
comparative study performed in late nineties revealed that gel-type resins are superior 
to macroporous resins in SPPS in both product yield and purity.78  
1.5 Linkers	
The substrate is attached to the functionalized solid support with a fragment called a 
linker. Currently there are hundreds of different linkers developed for a wide range of 
applications.94 Only few examples will be discussed below. Majority of the linkers can 
be regarded as support bound protecting groups, i.e. the substrate containing a func-
tional group is attached to the linker moiety by a cleavable bond that is stable under 
synthesis conditions. In addition, there are so called traceless linkers which at the 
cleavage give a new C-H or C-C bond at the attachment point of the linker.95  
The linkers can be classified in several ways, especially by the cleavage chemistry96 
(electrophilic, nucleophilic, photolysis, metal-assisted, reductive, oxidative, cycloaddi-
tion or cycloreversion) and by the functional group obtained after cleavage.95,97,98 An 
ideal linker should fulfil several criteria95, the primary properties being high yielding 
and easy attachment of the starting material, stability under a variety of synthesis con-
ditions, and efficient cleavage reaction under conditions that do not damage the prod-
ucts. In addition, particularly in production of large libraries, the linker should be 
readily available and cheap, the work-up should be easy and cleavage should not intro-
duce impurities that are difficult to remove.  
Usually the substrate is attached to a preformed linker on the solid support. In some 
cases, though, it is favourable to attach the substrate to the linker in solution phase, 
purify this conjugate and attach it to the support.99 The latter method can be used, for 
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example, if the preformed linker is unstable in storage, the loading reaction is disfa-
voured because of steric or electronic reasons or the loading reaction leads to unwanted 
side products which would contaminate the end products.95 
Additional atoms that may be located between the polymer and the linker moiety con-
stitute a spacer. Spacers can be introduced to increase mobility or solvation of the sub-
strate. An example of increased mobility is offered by narrower line widths in NMR 
spectra of Tentagel bound molecules compared to polystyrene resin without a PEG 
spacer.100  However, the mobility of the pendant group on a properly swollen polysty-
rene resin may well be sufficiently high to warrant good reaction kinetics.38,101 For 
example, in peptide synthesis, the distance from the support has generally no signifi-
cant influence on the synthetic efficiency.102 Another reason for using a spacer may be 
the need to modify steric or electronic environment.103–105 
1.5.1 Acid	Labile	Linkers	
The chloromethylpolystyrene resin (i.e. Merrifield resin) has been used for the attach-
ment of carboxylic acids since the early days of SPS.5,106 The benzyl ester linkage 
formed requires a strong acid, such as HBr in TFA, TFMSA107 or HF108 for cleavage 
reaction. Because it was found out that the benzyl ester linkage is not fully stable in 
50% TFA in DCM109  used for deprotections in tert-butyloxycarbonyl/benzyl (Boc/Bn) 
peptide chemistry (vide infra), PAM (phenylacetamidomethyl) linker with electron 
withdrawing acetamidomethyl group para to the peptidyloxymethyl was introduced.110 
The foregoing demonstrates the fact that as the stability of the cation formed upon the 
cleavage reaction decreases, the acid stability of the linker increases. Thus electron 
withdrawing groups increase stability and electron donating groups increase lability of 
benzyl type linkers in acid (Figure 2). 
 
Figure 2. Stability of cations formed upon cleavage of some acid labile linkers. Labil-
ity of the corresponding linker increases from left to right. 
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Wang or para-alkoxybenzyl alcohol linker (Figure 3) that has an electron donating 
group in para position is cleaved in milder conditions, i.e. 50% TFA in DCM.111 
SASRIN (Super acid sensitive resin)112 or 2-chlorotrityl linkers113 are very labile to-
wards acids: peptide acids can be cleaved from both with 20% hexafluoro-2-propanol 
in DCM.114 One advantage of 2-chlorotrityl linker compared to the alkoxybenzyl alco-
hol linkers is that the linker is resistant to nucleophilic attack while especially Wang 
linker is labile towards nucleophiles which can be a problem in certain reactions. An-
other important mild acid cleavable linker is Rink115 in its different forms. It is used 
especially for synthesis of peptide amides by 9-fluorenylmethyloxycarbonyl/tert-butyl 
(Fmoc/t-Bu) protection strategy.116 An example of an amide linker for milder cleavage 
conditions is Sieber amide linker117 which is cleavable by 1% TFA in DCM while 4-
methylbenzhydrylamine or MBHA resin 118 , which has sufficient stability towards 
TFA, is used in Boc/Bn SPPS. Although only carboxylic acids and amides are men-
tioned here, these linkers allow release of a wide variety of leaving groups. 
 
Figure 3. Examples of acid labile linkers and their typical cleavage conditions.  
Introduction 23 
1.5.2 Linkers	Cleaved	by	Nucleophilic	Displacement	or	Other	Methods	
While some of the aforementioned benzyl ester linkers can be cleaved with nucleo-
philes, more appropriate ones for this purpose have been designed. The versatile 4-
(hydroxymethyl)benzoic acid (HMBA) linker119 (Figure 4) withstands acids but can be 
cleaved with a variety nucleophiles, e.g. 0.1 mol/L NaOH/dioxane, NH3/MeOH
119, 4% 
MeNH2/H2O, MeOH/TEA
120 or NH2NH2/DMF, producing diverse end groups. Anoth-
er example of nucleophilically cleaved linkers is succinyl linker,121,122 common in oli-
gonucleotide synthesis.  
 
Figure 4. HMBA, succinyl and safety-catch amide linkers and their typical cleavage 
conditions.  
A safety-catch linker123 requires a two-step cleavage process: the linker is first activat-
ed and then cleaved. The main advantage of using safety-catch linkers is that reaction 
conditions that would otherwise cleave the linker can be used in the synthesis prior to 
activation. Vinyl sulfone linker124 can be thought of as a safety-catch linker since a 
separate activation reaction is necessary to make the linking bond susceptible to cleav-
age reaction. The linker releases tertiary amines by β-elimination (Scheme 3) in basic 
conditions. The starting material, a secondary amine, is attached to a vinyl sulfone 
support by Michael addition forming a tertiary amine that is stable to a wide variety of 
reaction conditions. In the final steps of the synthesis, the amine is quaternarized and a 
short base treatment releases the tertiary amine to solution by Hoffman elimination. 
Another safety-catch linker is SCAL (Figure 4) that releases amides upon reductive 
acidolysis.125 In oxidized form, it is very stable towards acids and bases but reduction 
of the sulfoxide groups turns it acid labile. The activation can be made in a separate 
Introduction 24 




Scheme 3. Synthesis of tertiary amines using vinyl sulfone linker. 
1.6 Solid‐Phase	Peptide	Synthesis	(SPPS)	
Because of the wide range of biological functions of peptides and proteins127, it is easy 
to understand their importance in scientific research and thus the significance of work-
able peptide synthesis methods. Although peptides are constructed from relatively sim-
ple amino acids joined by peptide bonds, development of efficient synthesis methods 
has been a huge and still on-going process. There are several side-reactions that ham-
per the synthesis: epimerization, diketopiperazine formation, aspartimide formation, 
side-chain alkylation and incomplete deprotections to mention few. In addition, there 
are difficult sequences caused by aggregation of peptide chains, insoluble peptides or 
peptides that are difficult to purify.128 When the chain length increases, the yield limita-
tion discussed in chapter 1.2 has to be taken into account. To tackle these problems, 
numerous protection129, coupling130, cleavage131, ligation132,133 etc. methods have been 
developed. 
1.6.1 Synthesis	Principle	and	Protection	Strategies	
In solid-phase peptide synthesis, a peptide is constructed by successive deprotection, 
coupling and washing steps (Scheme 4). Before the coupling step, there is often a pre-
activation step for the entering protected amino acid. The main protection strategies 
used in SPPS are Boc/Bn and Fmoc/t-Bu134 methods. In the first method, Boc serves as 
a temporary protection for the α-amino group. It is removed by an acid (50% TFA in 
DCM) treatment in every synthesis cycle. In the standard method, there is a neutraliza-
tion step between TFA deprotection and coupling steps. Alternative simultaneous neu-
tralization and coupling can, however, give better results and can help to reduce pep-
tide chain aggregation.135 The side-chains of amino acids are protected permanently 
with benzyl or other protecting groups that are cleavable with strong acid at the end of 
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the synthesis. Additionally, there can be semi-permanent side-chain protections for on-
resin modification of the side-chains (e.g. cyclization) or permanent orthogonal protec-
tions that endure the detachment from the solid support. In an orthogonal protection 
scheme, any of the protecting groups can be selectively removed without affecting the 
other protecting groups present.57 
 
Scheme 4. The generalized solid-phase peptide synthesis principle. Boc/Bn chemistry 
contains additionally a neutralization step after deprotection. 
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Unlike Boc/Bn scheme, the Fmoc/t-Bu protection scheme is intrinsically orthogonal 
(Figure 5). The temporary Fmoc protection is removed with a base (20% piperidine in 
DMF) and the permanent t-butyl and Boc side-chain protections with acid (TFA) dur-
ing detachment from the solid support. Third orthogonal dimension is often obtained 
by allyl and allyloxycarbonyl protections which can be cleaved by palladium chemis-
try. In some cases, a quasiorthogonal protection strategy is selected, i.e. a protecting 
group can be removed selectively in milder conditions than other protecting groups in 
the system. For example, trityl group can be removed from serine, threonine, and tyro-
sine side-chains with 1% TFA in DCM leaving the linker as well as t-butyl and Boc 
protections intact. While the more flexible Fmoc/t-Bu method is by vast more popular 
currently, Boc/Bn SPPS is still being used and developed.105 
 
Figure 5. An imaginary example of Fmoc/t-butyl protection strategy with two addi-
tional orthogonal dimensions (Allyl and acetamidomethyl or Acm) on Wang linker. 
1.6.2 Peptide	Bond	Formation	
A peptide or amide bond is normally formed by a so called coupling reaction between 
carboxylic acid and amine (Scheme 5). This unification does not occur without activa-
tion at room temperature and high temperature required for direct condensation reac-
tion between the two would often lead to an undesired product mixture. There are nu-
merous peptide coupling reagents and methods in use130,136,137, starting from acid chlo-
rides by Fischer138.  
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Scheme 5. Peptide coupling reaction. 
Active ester method using coupling reagents (for the sake of readability the full names 
of the coupling reagents are only in the Abbreviations section) like DCC/HOBt139,140 or 
HBTU141 is currently the most popular. Among the wide variety of coupling reagents, 
HATU142 has been considered to be the most efficient, while there are currently several 
comparable alternatives like COMU143, HCTU144, HDMC145, and PyClock146.147  
During the activation and coupling reaction, there is a major risk of racemization of the 
activated entering amino acid or peptide.130 The racemization takes place base catalyti-
cally by direct enolization or through 5(4H)-oxazolone formation. For amino acids, the 
α-amino protecting group has an influence. Carbamates are less prone to form oxa-
zolones than acyl groups and protecting groups with electron-withdrawing moieties 
increase enolization. The base used in coupling reaction also influences the racemiza-
tion. Thus, using collidine, 2,3,5,6-tetramethylpyridine or octahydroacridine instead of 
ethyldiisopropylamine (DIEA) or N-methylmorpholine may facilitate to suppress rac-
emization.148,149 König and Geiger introduced in 1970 1-hydroxybenzotriazole (HOBt) 
additive for efficient racemization suppression.139 Later Carpino introduced an even 
better, although expensive, suppressant 1-hydroxy-7-azabenzotriazole (HOAt).142 Be-
cause HOBt and especially HOAt have explosive properties which may restrict their 
transportation, 2-cyano-2-(hydroxyimino)acetate (Oxyma) has been introduced. 150 
Oxyma has similar or better coupling efficiency and ability to suppress racemization 
than HOAt or HOBt. The majority of the currently used coupling reagents are based on 
these suppressants or 6-chloro-1-hydroxybenzotriazole151 which is a cheaper alterna-
tive to HOAt. 
Acid halides have long had only limited use in peptide chemistry, because of the hy-
drolytic instability of acid chlorides and frequent side reactions (e.g. racemization and 
cleavage of protecting groups). During last two decades they have gained some popu-
larity, much due to the work of Carpino and his group.152 Acid halides are especially 
suitable for peptide coupling reactions of extremely hindered amino acids or couplings 
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with weak amino nucleophiles.153,154 In situ activation using triphosgene (BTC)155,156 or 
tetramethylfluoroformamidinium hexafluorophosphate (TFFH)157 helps to tackle stabil-
ity and racemization issues. On the other hand, acid fluorides do not suffer from many 
of the problems related to acid chlorides. They are shelf stable, they are compatible 
with most of the protecting groups and because they do not form readily oxazolones, 
couplings do not suffer from racemization.  
 
 
Figure 6. Some commonly used (DCC/HOBt, HOAt or Oxyma Pure, HBTU) and most 
efficient (HATU, HCTU, COMU, HDMC, PyClock, BTC, TFFH) coupling reagents. 
1.6.3 Peptide	Synthesizers	
A variety of peptide synthesizers from micromole to industrial manufacturing scale are 
commercially available.158 There are single channel instruments and instruments capa-
ble of parallel synthesis.159 Especially the latter are often based on a robotic platform. 
Some of the modern peptide synthesizers can use microwave heating to facilitate the 
synthesis.160 In batch reactors, the support is in a vessel that is agitated during the reac-
tion. Addition of solvents and reagents occur either by applying a positive pressure on 
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the solvent or reagent flask for a preset time or by volumetric dispensing using digital 
injection pumps. In a batch reactor synthesis proceeds in discontinuous fashion: rea-
gents are added, reaction takes place, reagents are removed and resin washed. By con-
trast, in continuous flow system, the fluid flows through the column continuously and 
the reactant mixture can be recirculated until the reaction is ready. Because only part of 
the support is in contact with the concentrated reagent at a moment, smaller amounts of 
reagents are needed. The deprotection and acylation reactions can be continuously 
followed for example by UV absorbance of the effluent flow in Fmoc/t-Bu method. 
Currently batch synthesizers are considerably more popular than continuous flow syn-
thesizers. 
1.6.4 Cyclic	Peptides	
Cyclization is a general way to increase the conformational constrain to otherwise 
quite flexible peptide chain.161–163 It may lead to greater conformational integrity, in-
creased agonist or antagonist potency, prolonged biological activity, increased enzy-
matic stability, increased specificity for a particular receptor164   or increased cell-
permeability165. The biological activities that have been utilized include, for example, 
antibacterial, immunosuppressive, and anti-tumour activities.166 Many natural cyclic 
peptide hormones, such as calcitonin, oxytocin, somatostatin and vasopressin, are cy-
clic. Although macrocycles are promising drug molecules they have been relatively 
little exploited because they don’t fulfil the Lipinski rule of 5 of drug-likeness167 and 
their synthesis and screening has been considered challenging.168 Currently highly sta-
ble cyclotides169 and lasso peptides170 are considered as promising templates for drug 
design. An important application of peptide cyclization is conformational studies that 
include explorations of protein folding and determination of biologically active con-
formations of peptides.162–164 During the decades of peptide synthesis, several reviews 
of synthetic methods to prepare cyclic peptides have been published. 163,171–177 
1.7 Solid‐Phase	Organic	Synthesis	and	Combinatorial	Chemistry	
Combinatorial chemistry is a technique to synthesize rapidly a large set of compounds, 
i.e. a library, under similar reaction conditions from a set of building blocks.178 Typi-
cally the library is prepared on synthesizers which contain an array of reactors. The 
syntheses can be performed either in parallel fashion to obtain discrete compounds in 
separate reaction vessels or by so-called split-pool method pioneered by Furka,22,179 to 
obtain product mixtures. Initially the combinatorial chemistry libraries consisted of 
peptides, but the publication of Ellman’s benzodiazepine library21 showed that synthe-
sis of small molecule combinatorial libraries could be adapted to a solid support. After 
the successful application to combinatorial chemistry, the solid-phase organic synthesis 
started to stimulate wider interest although it had been studied already from the ’60s. 
Its initial dominance in combinatorial chemistry, measured by published articles, was 
overtaken by solution phase synthesis after a decade.180 A large portion of organic 
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transformations were adapted to solid support already by the end of ’90s181–185 and 
complex natural product derived libraries were developed186–188. Although majority of 
transformations were between carbon and heteroatom, many of the carbon–carbon 
bond forming reactions important for synthetic organic chemistry were also transferred 
to a solid support.189,190 Currently, even radical reactions have been utilized on a solid 
support.191  
1.7.1 Purine	Based	Compounds	in	Medicinal	Chemistry	
Purine is the most abundant N-heterocycle in the nature. Besides being a constituent of 
DNA and RNA, natural purine derivatives have a very wide range of biological func-
tions.192 Approximately 4–7% of all proteins encoded by the genome depend on purine 
nucleotides as co-factors or co-substrates for their function.193 These include G-protein 
coupled receptors and protein kinases which comprise the two most studied drug target 
classes currently.194,195 Figure 7 summarizes the potential applications of purine based 
drugs. Apart from being ubiquitous in nature, purine bicycle with its seven sites for 
substitution and well-established chemistry lends itself well for chemical manipula-
tion.193 Thus, it is an ideal scaffold for chemical library synthesis.  
A large and diverse family of G-protein coupled receptors (GPCRs) consists of trans-
membrane receptors that sense ligands outside the cell and activate G-protein inside 
the cell. G-protein activates then the corresponding inside signal transduction pathways 
and thus cellular responses. Adenosine receptors constitute a class of GPCRs that are 
activated by adenosine which is a major local regulator of tissue function.196 The ef-
fects of activation tend to be cytoprotective and aim at adapting the tissue or organ to a 
particular physiological stress condition taking place (e.g. hypoxia). Adenosine recep-
tor drugs are being developed, for example, against neurological disorders, autoim-
mune diseases, chronic pulmonary diseases, asthma, and cardiovascular disorders.196–
198 Selective antagonists and agonists for all the four human adenosine receptor sub-
types have been developed. Currently only one selective adenosine receptor drug, 
namely Lexiscan (Regadenoson) for radionuclide myocardial perfusion imaging, has 
been approved for clinical use but many others are undergoing clinical trials.196 
Protein kinases (PK) mediate and regulate the majority of the signal transduction in 
cells. The 538 human protein kinases control most of the important biological process-
es which makes them a very attractive target for drug development.199 The short of 
twenty regulatory approved PK inhibitor drugs are mostly used in treatment of differ-
ent cancers. PKs exert their function by catalysing the transfer of the terminal phos-
phate group of ATP to the hydroxyl group of serine, threonine or tyrosine residue of 
their protein substrate. The intracellular ATP concentration is high and the ATP-
binding site is highly conserved among protein kinases, which makes discovery of 
selective and potent PK inhibitors difficult. There are less conserved areas in the ATP 
Introduction 31 
binding pocket that do not participate in ATP recognition, and this can be used to in-
crease the selectivity. In addition, inhibitors that bind the inactive conformation of PK 
or bind outside ATP-pocket have been developed to tackle the problem.200 Although 
majority of the known kinase inhibitors are ATP-competitive, purine or xanthine core 
is relatively infrequently utilized. 
 
Figure 7. Potential applications of purine derivatives. Combinations of various substit-
uents (1, 2, 3, 4…) on the different positions (R1–R7) of the purine ring lead to inhibi-
tors of the different primary targets located inside the circle (PDEs, phosphodiesterase; 
pol, DNA or RNA polymerase; Src, Src tyrosine kinase; CatK, cathepsin K = cysteine 
protease; A2AR, adenosine receptorA2A; Cdk, cyclin-dependent kinase; CRH, cortico-
tropin-releasing hormone; HSP90, heat-shock protein-90; IP3K, inositol-1,4,5-
triphosphate-3-kinase; EST, oestrogen sulfotransferase; β-AST, β-arylsulfotransferase). 
Some potential therapeutic applications are noted at the outside of the circle (CML, 
chronic myeloid leukaemia). The question mark indicates that either the primary target 
or the possible application(s) is (are) not known. The figure is reworked from refer-
ence193. 
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2. Aims	of	the	Thesis	
The studies included in this thesis have their origins in the national Tekes (the Finnish 
Funding Agency for Technology and Innovation) Drug 2000 technology program. The 
objectives of the subproject was to i) develop solid-supported methods to produce li-
braries of bicyclic peptides, bioconjugates, and biimidazoles, ii) prepare the libraries, 
and iii) study the use of bicyclic peptides as artificial receptors or drug carrier mole-
cules and biimidazoles as protein kinase inhibitors and finally to transfer the research 
results to designated pharmaceutical companies. The biimidazole library method de-
velopment spawned additionally synthesis methods of 7-substituted 3H-imidazo[2,1-
i]purines and 7-substituted 3-β-D-ribofuranosyl-3H-imidazo[2,1-i]purines that were 
targeted towards adenosine receptors. In addition to studies included here, the research 
group focused on solid-supported synthesis of various branched201 or cyclic202–204 pep-
tide structures and peptide205,206 or oligonucleotide207,208 glycoconjugates. 
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3. Results	and	Discussion	
3.1 Bicyclic	Peptides	with	Three	Parallel	Peptide	Chains	(II)	
The underlying idea of the cyclic peptides discussed here was that they contained three 
dissimilar parallel peptide chains and that the peptides were homodetic, i.e. all covalent 
linkages between the amino acids are peptide bonds. This meant that two branching units 
to cap the amino and carboxy termini of the chains were needed. Moreover, because the 
synthesis was to take place on a solid support and a possibility for further conjugation 
was required, a functional group for anchoring or conjugation was needed in one of the 
branching units. Hence, orthogonally protected α,α-bis(aminomethyl)-β-alanine (1, Fig-
ure 8) and N-succinyliminodiacetic acid (2) were selected for the purpose and synthe-
sized. Although 1 is chiral, no attempt to separate the enantiomers or to devise a route 
that produced optically pure compound was taken. Instead, it was thought that having 
both enantiomers present gave a better chance for success in the second cyclization be-
cause the three dimensional structure of the monocyclic precursors were unknown.  
 
Figure 8. Branching units used in the synthesis of bicyclic peptides. 
3.1.1 Synthesis	of	the	Orthogonally	Protected	Branching	Unit	1	(I)	
The orthogonally protected branching unit 1 (3-{[(allyloxy)carbonyl]amino}-2-({[(9H-
fluoren-9-ylmethoxy)carbonyl]amino}methyl)-2-({[(tert-butoxy)carbonyl]amino}-
methyl)propanoic acid) was initially synthesized in low yield by a fifteen step time 
consuming route from pentaerythritol. After several different approaches based on 
different starting materials, a somewhat shorter and much faster route was devised 
(Scheme 6). The branching unit was synthesized from 2,2-bis(bromomethyl)-1,3-
propanediol (3) in eleven steps in about three per cent overall yield. One of the hy-
droxyl groups of the starting material was first 4-methoxytritylated (MMTr). Only half 
equivalent of 4-methoxytrityl chloride was used to maximize the yield of the monopro-
tected product. Nucleophilic substitution of the bromo substituents with azide ion gave 
bis(azidomethyl) compound 5 which was reduced to 6 with sodium borohydride (1.2 
equiv) and 1,3-propanedithiol (0.1 equiv)209. This selective reduction of only one azido 
group was the key step of the synthesis. Because longer reaction times or higher excess 
of reducing agents gave product mixtures, the reaction was stopped after 45% for-
mation of the monoamino product. The starting material was recycled. After Boc pro-
tection of the amino group, the remaining azido group was subjected to Staudinger 
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reduction210 and the formed amino group was protected with allyloxycarbonyl (Alloc) 
chloride giving 9. The free hydroxyl function was replaced with phthalimidoyl group 
by Mitsunobu reaction211,212. Removal of the MMTr group under mild conditions by 
1% iodine in methanol213 exposed the second hydroxyl function, which was oxidized in 
moderate yield to carboxylic acid (12) with Jones reagent214. In early studies, com-
pound 12 was used as the branching unit in the SPPS. The removal of phthaloyl protec-
tion on solid support215 was, however, slow, requiring elevated temperatures and in 
some cases reiterations. Thus, a more readily removable Fmoc protection was intro-
duced. Phthaloyl protection was removed by hydrazinolysis in the presence of allyl 
alcohol to protect the Alloc group,216 and the Fmoc group was introduced to yield 1.  
 
Scheme 6. Synthesis of N-Alloc-N′-Fmoc-N″-Boc-α,α-bis(aminomethyl)-β-alanine 
from 2,2-bis(bromomethyl)-1,3-propanediol. Reagents and conditions:  i) MMTrCl, 
pyridine, ii) NaN3, LiCl, DMF, pyridine, iii) NaBH4, HS(CH2)3SH, NEt3, iPrOH, iv) 
Boc2O, NaOH, MeCN, v) PPh3, NH3, aq, vi) AllocCl, NEt3, dioxane, vii) phthalimide, 
PPh3, DEAD, THF, viii) I2, MeOH, DCM, ix) CrO3, H2SO4, H2O, acetone, x) NH2NH2, 
allyl alcohol, DMF, dioxane, xi) FmocCl, K2CO3, H2O, MeCN. 
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3.1.2 Synthesis	of	the	Orthogonally	Protected	Branching	Unit	2	
Synthesis of the second branching unit N-(4-allyloxy-4-oxobutanoyl)iminodiacetic acid 
2 was more straightforward. Because 2 was to be coupled to the peptide as a cyclic 
anhydride, only one protecting group, namely allyl ester, was required. Accordingly, 
succinic anhydride was monoallylated in allyl alcohol–pyridine mixture giving 15 
(Scheme 7). Di-tert-butyl iminodiacetate and 15 were condensed by HOAt/DCC acti-
vation. In the third step, tert-butyl protections were removed with TFA giving 2. 
 
Scheme 7. Synthesis of N-(4-allyloxy-4-oxobutanoyl)iminodiacetic acid 2. Reagents 
and conditions: i) allyl alcohol, pyridine, ii) HOAt, DCC, di-tert-butyl iminodiacetate, 
pyridine, DMF, iii) TFA:DCM 2:1. 
3.1.3 Synthesis	of	the	Bicyclic	Peptides	
Hydroxymethyl polystyrene was first derivatized with an H-Leu-Leu-Gly-OH spac-
er.217 Accordingly, glycine was attached to the resin by the symmetrical anhydride 
method, and the chain was elongated either manually or on a peptide synthesizer. The 
branching unit 1 was then coupled by HATU/DIEA activation to obtain tetrapeptide 17 
(Scheme 8) bearing three orthogonally protected amino groups. The protections were 
removed one at a time and the corresponding peptide chains were constructed either by 
coupling of dipeptide segments (18a and 18b ) or by stepwise synthesis (18c and 18d) 
In the latter case, the chains on the Fmoc and Boc protected amino groups were assem-
bled by stepwise coupling using Fmoc and Boc protected amino acids, respectively. 
The third, Alloc protected Phe-β-Ala branch, was introduced as a segment in all pep-
tides. Both approaches gave satisfactory coupling yields. The second branching unit (2) 
was converted to a cyclic anhydride with 1-ethyl-3-(3-dimethylaminopro-
pyl)carbodiimide (EDAC) activation in DMF and coupled to the deprotected peptide 
chains P1. After the Boc protection was removed from the chains P2, the supported 
peptides were cyclized by HATU/DIEA activation in 5 hours. Because 2 is not chiral, 
there is no risk of epimerization even during such a slow cyclization reactions.218 
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Scheme 8. Synthesis of bicyclic peptides. Reagents and conditions: i) SPPS, ii) piperi-
dine, DMF, iii) N-(4-allyloxy-4-oxobutanoyl)iminodiacetic anhydride, DMF, iv) TFA, 
DCM, v) HATU or PyBOP, DIEA, DMF, vi) Pd(OAc)2, PPh3, Bu3SnH, AcOH, DCM, 
vii) 30% HBr/AcOH, thioanisole, pentamethylbenzene, TFA 
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While the cyclizations of 19a and 19b, containing a flexible -alanine residue in both 
of the participating peptide chains, proceeded well, the corresponding reaction with 
19c and 19d consisting only of α-amino acids yielded a more complex product mix-
tures. The Alloc and allyl ester protecting groups were removed simultaneously from 
the monocyclic peptides using the palladium-tributyltin hydride chemistry.219 The sec-
ond cyclization of compounds 20a and 20b was then carried out by the HATU/DIEA 
chemistry (16 h) as before. By contrast, a phosphonium coupling reagent (PyBOP220) 
was used for the second cyclization of 21c and 21d because 1,1,3,3-
tetramethylguanidino derivatives221 could be detected among the side products. In ad-
dition, the solvent was changed from DMF to a 1:4 mixture of DMSO and NMP, and 
the reaction time was extended to 22 h. The cyclization reaction of 21d was repeated 
since all the starting material had not disappeared. Despite these changes, the second 
cyclization reaction of 21c and 21d led to a complex reaction mixture and markedly 
decreased yield, probably due to polymerization on the support. Acid-catalysed cleav-
age from the support gave 22a-d as free carboxylic acids.  
All four peptides were obtained in pure state by HPLC, but in low yield. Only the most 
flexible peptide 22a was obtained as a reasonably pure crude product. The compound 
appeared as a pair of diastereomers that were separated by HPLC (Figure 9). Isomer-
ism originates from the racemic chiral branching unit 1. Diastereomers of peptides 
22b–d could not be separated with the HPLC system used. In addition, two unsuccess-
ful attempts to synthesize more rigid bicyclic peptides having a smaller ring size and 
no β-alanine residues were made. Accordingly, the described methodology allows the 
preparation of some homodetic bicyclic peptides on a solid support, but its applicabil-
ity to library synthesis is severely limited. 
 
Figure 9. HPLC trace of the crude diastereomeric pair of 22a cleaved from the resin 
(RP HPLC 0–100% acetonitrile, 0.1% TFA, λ = 215 nm). 
3.2 7‐Substituted	3H‐Imidazo[2,1‐i]purines	(III)	
The amidine-like moiety of adenine derivatives is known to undergo a cyclization reac-
tion with α-halocarbonyl compounds (Scheme 9). 222 – 228  The reaction forms ring-
extended 3H-imidazo[2,1-i]purines (24) which are also called 1,N6-etheno adducts.  
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Scheme 9. Proposed mechanisms of cyclization of adenine derivatives with α-
halocarbonyl compounds229 (a) and intervening pyrimidine ring acid230 (b) or base231 
(c) catalysed hydrolysis. 
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This bridging makes the intervening pyrimidine ring susceptible to acid232 or base233 
hydrolysis which converts 3H-imidazo[2,1-i]purines to 5′-amino-2,4′-biimidazoles 
(25). These reactions have been utilized, for example, for the synthesis of fluorescent 
adenine derivatives234 and 2-deuterated235 or 2-substituted236 adenine derivatives when 
combined with pyrimidine or 1,2,3-triazine ring closing233 and etheno adduct remov-
al237. The synthesis of biimidazole library was planned to utilize these techniques trans-
ferred to a solid support. Adaptation of the pyrimidine ring opening reaction to a 
mixed-phase reaction, however, turned out to be challenging. It was difficult to find 
reaction conditions that yielded sufficiently pure products. Therefore, it was decided to 
concentrate first on preparation of 3H-imidazo[2,1-i]purines which are by themselves 
interesting molecules for drug discovery.  
Bromomalonaldehyde238 is known to react with adenine derivatives in aqueous and 
organic solvents yielding 1,N6-formyletheno adducts.224 In aqueous solvents, the reac-
tion mainly produces 1,N6-etheno adducts because of the competing hydrolytic de-
formylation that takes place before cyclization of the carbinolamine intermediate.229 
Under the most favourable conditions, when pH is below 3.5, the two products are 
formed in about equimolar ratio. Then again in DMF, low yields have been earlier 
reported.239 To optimize the reaction and the subsequent reductive amination on a pol-
ystyrene solid support, N-[(adenin-9-yl)acetyl]phenylalanine-Wang resin was chosen 
as the model polymer. Commercial Nα-Fmoc-phenylalanine-Wang resin was deprotect-
ed and loaded with [N6-(4-methoxytrityl)adenin-9-yl]acetic acid240 (Scheme 10). The 
4-methoxytrityl protection was removed with 3% dichloroacetic acid in DCM. There-
after, the polymer was neutralized with pyridine in DCM, washed and dried. The pol-
ymer was divided into portions and tested for the cyclization reaction under various 
conditions (Table 4.). In unbuffered DMF, the reaction proceeded slowly (entries 10, 
15, 16, 19, and 20). During the first three hours, product was formed in 55% yield on 
using five equivalents of bromomalonaldehyde, but doubling the reaction time in-
creased the yields only by few per cent. Similarly, doubling the concentration of bro-
momalonaldehyde did not much improve the situation. Basic conditions decelerated 
(entries 1–7, and 9) and moderately acidic conditions accelerated the reaction (entries 
8, 11-14, 17, 18, 21, and 22). While addition of triethylamine to the reaction mixture 
was disadvantageous, 2,6-lutidine/formic acid mixture worked better. The reaction rate 
was relatively insensitive to the ratio of formic acid and 2,6-lutidine. Several different 
compositions of the mixture of formic acid and 2,6-lutidine has been successfully uti-
lized since. For the synthesis of 27 1:1 ratio was used. 
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Table 4. Optimization of formyletheno adduct formation on polystyrene in DMF at 60 
°C using five equivalents of bromomalonaldehyde.  
Entry Buffer Equiv.a t /min. Productb /%
  1 Acetic acid / triethylamine 10/10 330 14
  2 Formic acid / triethylamine 10/10 330 56
  3 Formic acid / triethylamine 10/10 1320 19
  4c,d Formic acid / triethylamine 20/20 270 0
  5e Formic acid / triethylamine 20/20 270 45
  6 Formic acid / triethylamine 28/10 270 32
  7f Formic acid / triethylamine 10/10 270 18
  8 Formic acid / 2,6-lutidine 10/10 270 95
  9  2,6-lutidine 0/10 65 47
10 — 65 51
11 Formic acid / 2,6-lutidine 50/10 65 53
12 Formic acid 50/  0 65 55
13 Formic acid / 2,6-lutidine 100/10 65 68
14g Formic acid / 2,6-lutidine 150/10 65 58
15 — 180 55
16c — 180 64
17 Formic acid / 2,6-lutidine 30/10 180 87
18c Formic acid / 2,6-lutidine 60/20 180 92
19 — 360 62
20c — 360 68
21 Formic acid / 2,6-lutidine 30/10 360 93
22c Formic acid / 2,6-lutidine 60/20 360 92
a) Compared to support bound adenine 
b) Calculated from the HPLC chromatogram peak areas:  
A(product)/A(product)+A(starting material)×100%. 
c) 10 equiv. of bromomalonaldehyde 
d) Reaction at room temperature 
e) 15 equiv. of bromomalonaldehyde added in three batches. 
f) Solvent was DMSO/NMP 1/4. 
g) According to mass spectrum of the reaction mixture, some product and starting 
material were cleaved during the reaction. 
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Scheme 10. Synthesis of the model 3H-imidazo[2,1-i]purine 28 for reaction optimiza-
tion. Reagents and conditions: i) piperidine, DMF, ii) [N6-(4-methoxytrityl)adenin-9-
yl]acetic acid, TBTU, DIEA, DMF, iii) 3% dichloroacetic acid, DCM, iv) bromomalo-
naldehyde, HCO2H, 2,6-lutidine, DMF, v) BnNH2, NaCNBH3, HCO2H, DMF, MeOH, 
vi)  Ac2O, DCM, vii) 1:1 TFA, DCM. 
Reductive amination of the support-bound 3H-imidazo[2,1-i]purine-7-carbaldehyde 
(27) with either sodium triacetoxyborohydride or sodium cyanoborohydride was slow 
when acetic acid was used as a catalyst. After 24 hours, 30% of 27 remained unreacted 
on using ten equivalents of benzylamine and sodium cyanoborohydride in DMF acidi-
fied with 4% acetic acid. The reaction was even slower on using corresponding amount 
of sodium triacetoxyborohydride. Replacing acetic acid with formic acid accelerated 
the amination so that it was completed in 5 hours. When amination with a sterically 
hindered amine, such as diisopropylamine or diethylamine, was attempted, the starting 
aldehyde persisted throughout the reaction. Reduction to 7-hydroxymethyl-3H-
imidazo[2,1-i]purine was not detected. 241,242 Sodium cyanoborohydride in DMF con-
taining 4% formic acid and 6% methanol was, hence, used for the subsequent reductive 
aminations. The secondary amines obtained by reductive amination may react further 
with another carbonyl compound forming bisalkylated products.241 To prevent this 
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side-reaction, excess of amine and a sufficient pre-equilibration for rate-determing 
imminium formation can be used. Although 10 equivalents of benzylamine and a short 
30 minutes reaction time for imine formation prior to sodium cyanoborohydride addi-
tion were used, about 6% of bisalkylated product was formed through an intraresin 
reaction. 
After suitable reaction conditions for the solid-phase synthesis of the model compound 
28 were found, a test synthesis was performed. No further adjustments to reaction con-
ditions were made except that the reaction time for the ring forming reaction was 4 
hours. Solid-supported N-benzyl(imidazo[2,1-i]purin-7-yl)methylamine moiety was 
acetylated with acetic anhydride in DCM. Acidolytic release from the support with 
50% TFA in DCM gave N-{[7-(N-benzylacetamidomethyl)imidazo[2,1-i]purin-3-
yl]acetyl}phenylalanine (28) in 29% overall yield after HPLC purification. Figure 10 
shows the HPLC trace of the crude product mixture. The trace shows that the reactions, 
except acetylation, were not completed and, aside from bisalkylated product formation 
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Figure 10. HPLC trace of crude N-{[7-(N-benzylacetamidomethyl)imidazo[2,1-
i]purin-3-yl]acetyl}phenylalanine (28) (RP HPLC, 0–100% acetonitrile, 0.1% TFA,  
= 220 nm). The products were identified mass spectrometrically. 
A small library of (imidazo[2,1-i]purin-7-yl)methylamines 32 was then synthesized on 
a solid-support utilizing the method described above (Scheme 11). Commercial deoxy-
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the support. Unlike the stable phosphodiester bond, the N-glycosidic bond between 2′-
deoxyribose and ethenoadenosine ring system can be cleaved by relatively mild acid 
treatment, i.e. with 5% TFA in DCM in one hour. The N-glycosidic bond nevertheless 
withstands the formic acid treatments applied to generate the additional imidazole ring 
and subsequent reductive amination of the formyl group.  
 
Scheme 11. Synthesis of N-substituted (imidazo[2,1-i]purin-7-yl)methylamines. 
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A (4-methoxytrityloxy)butyric acid spacer was first attached to aminomethylpolysty-
rene resin using diisopropylcarbodiimide (DIC)/HOBt activation. After acidolytic 
deprotection, N6-benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine 3′-(2-
cyanoethyl-N,N-diisopropylphosphoramidite) was coupled to the exposed hydroxy 
functions by 4,5-dicyanoimidazole activation and oxidized to a phosphate triester (29) 
with aqueous iodine. The 4,4′-dimethoxytrityl group was removed with 3% dichloroa-
cetic acid in DCM to avoid the risk that partly detaching dimethoxytrityl cation could 
be engaged in some side-reaction during the following synthesis steps. The N-benzoyl 
and O-(2-cyanoethyl) protections were cleaved by refluxing the resin in THF contain-
ing aqueous sodium hydroxide. The exposed 5′-hydroxy and phosphodiester groups did 
not disturb the subsequent reactions. The deprotected support-bound 2′-
deoxyadenosine was then treated with bromomalonaldehyde under the conditions de-
scribed in the foregoing. The desired support-bound 3-(2′-deoxy-β-D-erythro-
pentofuranosyl)-3H-imidazo[2,1-i]purine-7-carbaldeyde (30) was formed in an almost 
quantitative yield, as seen from the HPLC trace of the acidolytically released crude 
product (Figure 11).  
5 1 0 1 5 2 0 2 5 3 0 
Figure 11. HPLC trace of crude 3H-imidazo[2,1-i]purine-7-carbaldehyde cleaved from 
the resin 30 (RP HPLC, 0–100% MeCN, 0.1% TFA,  = 220 nm). 
The scope of reductive amination of 30 was tested with a set of nine amines with vary-
ing steric hindrance or substituent inductive effects (32a–32i, Figure 12). It was ob-
served from the HPLC traces that after one hour imine formation and subsequent four 
hours reduction step, aniline (32a) and unhindered primary amines (entries 32b–d) had 
reacted well producing 84–100% product, while sterically hindered primary amines, t-
butylamine and tris(hydroxymethyl)aminomethane (32e,f), gave only a 35% yield. 
Acyclic secondary amines, diethylamine and diisopropylamine (32g,h) did not react 
according to HPLC traces, although a clear product peak of 32g was observed by 
MALDI-TOF mass spectrometry. By contrast, among cyclic secondary amines, piperi-
dine (32i), reacted smoothly, giving a 73% yield. Benzylamine (32b) and t-butyl gly-
cine acetate (32d) both gave additionally 4% of bisalkylated products. The method is 
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thus suitable for unhindered amines, but sterically more demanding amines give lower 










































32a 100% 32b 84% (4.5%) 32c 92% 32d 91% (4.2%)
32e 36% 32f 35% 32g 0% 32h 0% 32i 73%
32j 88% (5.8%) 32k 91% (3.9%) 32l 74% 32m 80% 32n 80%



















Figure 12. The synthesized library of (imidazo[2,1-i]purin-7-yl)methylamines 32. The 
yields are calculated from RP HPLC chromatograms. Amount of bisalkylated products 
are in parentheses. 
Support 30 was then aminated with 4-aminobutyric acid or 4-aminobutyric acid t-butyl 
ester. Besides the expected 32j and 32k, 4–6% of bisalkylated side products were 
formed. In case of 4-aminobutyric acid, 7% of a lactamized product was additionally 
obtained, in all likelihood by cyanoborohydride activation.243-245 The lactam formation 
was verified by HPLC spiking and comparison of the mass spectra of the side product 
with 1-[(3H-imidazo[2,1-i]purin-7-yl)methyl]pyrrolidin-2-one (32q), synthesized by 
HBTU/DIEA mediated cyclization of 32j.  
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Reductive alkylations of 32j with acetaldehyde, glycolaldehyde dimer or glyoxylic 
acid monohydrate gave compounds 32l–n. Sodium cyanoborohydride and formic acid 
were used like in the reductive aminations discussed above. With ten equivalents of 
aldehyde, three hours reaction time was sufficient to drive the reactions to completion. 
Compound 32k was, in turn, acylated with acetic anhydride and with Fmoc protected 
glycine by TBTU/DIEA activation to obtain 32o and 32p, respectively. Both reactions 
were completed in one hour. Likewise, the above mentioned lactamization was com-
pleted in one hour. N-Benzyl-N-[(3H-imidazo[2,1-i]purin-7-yl)methyl]acetamide (32r) 
was synthesized as 28, except that the reductive amination was repeated before the 
acylation. 
3.3 4(5),1´,5´‐Trisubstituted	2,4´‐Biimidazoles	(IV)	
After the method for the synthesis of 7-substituted 3H-imidazo[2,1-i]purines was de-
vised, the opening of the intervening pyrimidine ring was re-examined.  Many prob-
lems in the base catalysed hydrolysis were encountered, the main ones being side-
reactions, problems in isolating the product and most importantly the lack of reliable 
detection of the products formed. Shifting from MALDI-TOF to LC-ESI-Q mass spec-
trometry facilitated the studies so that methods for both base and acid catalysed hy-
drolysis on solid support were developed (Scheme 12). 
 
Scheme 12. Intervening pyrimidine ring opening of 7-formyl 3H-imidazo[2,1-i]purine 
on a solid support. Reagents and conditions: i) piperidine, DMF, ii) 2-(7-formyl-3H-
imidazo[2,1-i]purin-3-yl)acetic acid 36c, TBTU or HATU, DIEA, DMF, iii) 0.08 
mol/L NaOH, 1:1 H2O/THF 55 °C for base hydrolysis or 3.6 mol/L
 HCl in dioxane, 
10% H2O for acid hydrolysis. 
For the base catalysed hydrolysis, aminomethyl NovaGel resin was loaded with Rink 
amide linker giving a 0.5 mmol/g loading. It had been observed earlier that Wang link-
er did not withstand the conditions required for the hydrolysis. NovaGel was used be-
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cause it has better swelling properties than polystyrene in the high water content sol-
vent mixture used in the hydrolysis step. The resin was capped and derivatized consec-
utively with an amino acid (Fmoc-valine) and 2-(7-formyl-3H-imidazo[2,1-i]purin-3-
yl)acetic acid (36c, Scheme 13). Coupling of 36c turned out to be somewhat tricky. In 
spite of limited solubility, the compound could still be dissolved in a mixture of DMF 
and DIEA. After adding the coupling reagent, the active ester started to precipitate 
which was problematic for a solid-phase reaction. The precipitate filled the pores of the 
resin and clogged the frit of the synthesis column. Thus, the reaction rate was retarded 
and washing of the resin was difficult. Initially, TBTU was used as the coupling rea-
gent, and it turned out to be advantageous to add the dissolved 36c to the resin before 
the coupling reagent that was suspended in a small amount of DMF. Later, more effi-
cient HATU was used instead of TBTU, although, very long reaction times were still 
needed. Extensive washing was required to remove the surplus reagents from the sys-
tem. The hydrolysis step required overnight reaction at 55 °C when 0.08 mol/L sodium 
hydroxide in a 1:1 mixture (v/v) of THF and water was used. 
 
Scheme 13. Synthesis of 2-(7-formyl-3H-imidazo[2,1-i]purin-3-yl)acetic acid (36c) 
and 2-(5ʹ-amino-5-formyl-1H,1ʹH-2,4ʹ-biimidazol-1ʹ-yl)acetic acid (37) Reagents and 
conditions: i) HCBr(CHO)2, HCO2H, 2,6-lutidine, DMF, ii) HCl (aq.), iii) TFA/DCM 
HMBA polystyrene resin was used for the acid-catalysed hydrolysis. The resin was 
derivatized in the same way as the Rink amide resin. The hydrolysis was carried out as 
an overnight reaction at room temperature using 3.2 mol/L HCl in a 9:1 mixture (v/v) 
of dioxane and water. The conditions were harsh enough to cleave part of the material 
from the resin during the hydrolytic ring-opening. While the solid-supported hydrolysis 
makes it possible to exploit 3H-imidazo[2,1-i]purines that have different substituents at 
7 or 8 positions, we decided to concentrate on 7-formyl-3H-imidazo[2,1-i]purine in the 
library synthesis. Therefore, it was sensible to perform the pyrimidine ring hydrolysis 
in solution and couple the formed 2-(5ʹ-amino-5-formyl-1H,1ʹH-2,4ʹ-biimidazol-1ʹ-
yl)acetic acid (37, Scheme 13) to commercially available supports loaded with various 
amino acids.  In this way, convergence kept the number of synthesis steps on support 
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lower and parallel synthesis of sub-libraries was facilitated. The core structure 37 of 
the library was synthesized in two-steps from ethyl 2-(adenin-9-yl)acetate (35a) and 
bromomalonaldehyde. The straightforward route did not require chromatographic puri-
fications because both products of the route precipitated from the reaction mixture in a 
sufficiently pure state. Thus, N1 and N6 of the adenine moiety of 35a (purine number-
ing) were bridged with a formyletheno group under the conditions developed for the 
solid support synthesis (see 3.2). The pyrimidine ring of the resulting 3H-imidazo[2,1-
i]purine derivative (36a) was opened and the ethyl ester protection was removed simul-
taneously with 2 mol/L hydrochloric acid giving a white or yellowish hydrochloride 
product that precipitated from the solution. Attempted base-catalysed hydrolysis led to 
a dark brown product mixture.  
A small sample library consisting of 22 members was then synthesized, in a parallel 
manner, on Wang polystyrene resins loaded with Fmoc protected amino acids. 2-(5ʹ-
Amino-5-formyl-1H,1ʹH-2,4ʹ-biimidazol-1ʹ-yl)acetic acid 37 was utilized as a trivalent 
scaffold. The carboxylic acid group was diversified first by attaching it to leucine, as-
partic acid, tryptophan, or serine resin. The second diversification point was the formyl 
group which was derivatized either by oximation, hydrazone formation or reductive 
amination. The third point, 5ʹ-amino group, was acylated. After syntheses the products 
were cleaved from the resin and purified by RP HPLC for the analysis.  
Coupling of 37 to the deprotected resin required some adjustments to the standard cou-
pling methods, because 37 and its 1-hydroxybenzotriazole ester are sparingly soluble 
in DMF or DMF/DIEA. Thus, 37 was dissolved in warm dry pyridine and HBTU in 
DMF. The combined solutions were added onto the solid support (Scheme 14) and the 
reaction was shaken for seven hours to ensure completion of the coupling. Extensive 
washing was required as with the coupling of 36c. Each of the supports obtained, 38a-
d, was divided into three portions. The first portions were oximated with methoxy-
amine in pyridine. The hydrazone formation of the second portion was tested with 2,4-
dinitrophenylhydrazine (DNPH) and phenylhydrazine. Hydrazones are much more 
reactive than oximes246, 247 and, hence, there was an increased risk of undesired side 
reactions during subsequent synthesis steps. Unfortunately, this turned out to be the 
case. While 2,4-dinitrophenylhydrazone 40a reacted cleanly to single main products 
(43b, 45a) upon subsequent acylations of the 5ʹ-amino function, the phenylhydrazone 
gave a product mixture. In contrast to the 2,4-dinitrophenyl (DNP) derivative, which 
was deactivated by the strongly electron-withdrawing nitro groups, the sp3-hybridized 
nitrogen atom of the phenylhydrazone was sufficiently nucleophilic to react with iso-
butyryl and benzoyl chlorides. The N-acylated phenylhydrazones formed were partially 
decomposed to the corresponding formylbiimidazoles and 1-phenylhydrazines during 
acidic cleavage from the support. An attempt to isobutyrate the 5ʹ-amino function be-
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fore hydrazone formation did not improve the situation, because the isobutyryl group 
was cleaved off under the conditions needed for the hydrazone formation. 
 
Scheme 14. Reagents and conditions: i) 20% piperidine in DMF, ii) 3, HBTU, pyri-
dine, DMF, iii) R1ONH2·HCl, pyridine, iv)R
2NHNH2, AcOH, DMF, heating, v) mor-
pholine, HCO2H, NaCNBH3, MeOH, DMF. 
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Half of the remaining 38c and 38d were oximated with phenoxyamine instead. Oxima-
tion circumvented the acylation problem still yielding an analogous structure. The third 
portion of 38a-d was aminated with morpholine by using a method developed earlier 











































V = variable group
39-41
 
Scheme 15. Reagents and conditions: i) 2.5% H2O, 2.5% triisopropylsilane in TFA, ii) 
BzCl, pyridine, iii) Ac2O, pyridine, iv) isobutyryl chloride, pyridine. a) For annotation 
of variable groups see Table 5. 
The 5ʹ-amino group, which was the third diversification point of the biimidazole scaf-
fold, was challenging to derivatize. It is relatively unreactive, and if a substitution reac-
tion takes place, there is a risk of further reactions, e.g. cyclization to the outer imidaz-
ole ring. In addition, there are other reactive groups in the molecules, which limit the 
selection of available chemistries. Fmoc loadings and HLPC-MS data from preliminary 
experiments carried out with active esters or anhydride activated Fmoc protected ami-
no acids revealed that coupling efficiency was not sufficient. More reactive acyl hal-
ides seemed to work better. Therefore acyl halides were used in the library synthesis. 
Acetic anhydride also exhibited the required reactivity. The products 39-41 were di-
vided into portions and acylated either with benzoyl chloride, acetic anhydride or iso-
butyryl chloride (Scheme 15). Acyl halides reacted partially twice, but the second sub-
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stituent was easily removed by a short ammonia treatment. Intention of having com-
pounds with unsubstituted 5ʹ-amino group as library members was abandoned because 
they turned out to be labile (42a, 42b).  
Table 5. Members of the synthesized 4(5),1ʹ,5ʹ-trisubstituted 2,4ʹ-biimidazole test li-
brary and isolated overall yields. 
Compound V1 V2 V3 Isolated yield (%)a,b
42a Leu CHNOMe - 52 
42b Trp CHNNHPh - n.p. 
43a Leu CHNOMe Bz 44 
43b Leu DNPH Bz 38 
43c Leu morpholine Bz 33 
43d Asp CHNOMe Bz 57 
43e Asp CHNNHPh Bz 6 
43f Asp morpholine Bz 17 
43g Trp CHNOMe Bz 8 
43h Ser CHNOMe Bz 53 
43i Ser morpholine Bz 44 
44a Leu morpholine Ac 29 
44b Asp morpholine Ac 21 
44c Trp CHNOMe Ac 8 
44d Ser CHNOMe Ac 71 
44e Ser CHNOPh Ac 47 
45a Leu DNPH Ibuc 36 
45b Asp CHNOMe Ibu 45 
45c Asp CHNNHPh Ibu n.p. 
45d Trp CHNOPh Ibu 7d
45e Trp morpholine Ibu 12 
45f Ser morpholine Ibu 25 
a) According to 13C NMR all as TFA salts except 43b,43e,44c, and 45e, b) n.p. = not 
purified, c) Ibu = isobutyryl, d) Combined yield of E and Z isomers 
The library members 42–45 (Table 5) were cleaved from the support with a 2.5:2.5:95 
mixture of water, triisopropylsilane and TFA. In most cases, the products were rela-
tively pure after cleavage but they were still purified by HPLC for the analyses (see IV 
supporting information for the HRMS and NMR analyses248). Figure 13 shows four 
illustrative HPLC traces of the crude products obtained. The isolated yields of the tryp-
tophan-derived compounds (43g, 44c, 45d,e) were low, although scavengers were 
used. Oximated products existed as inseparable E/Z isomers. Only the phenoxyamine 
analogue 45d could be separated by RP HPLC. The isomeric ratio of the methoxyami-
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nated products was approximately 1:2 according to the 1H NMR integrals. The isomers 
were identified by recording a nondecoupled 13C spectrum of 44d and measuring the 
1JCH coupling constants of oxyimino carbons of the isomers (Figure 14). It is known 
that for a hydrogen syn to the imine nitrogen lone-pair a larger 1JCH coupling constant 
is expected than for anti.249,250 The 1JCH coupling constants of the oxyimino carbons of 
the isomers were 173 Hz (δ = 137.8 ppm) and 181 Hz (δ = 133.9 ppm). Therefore it 
was concluded that the carbon with 181 Hz coupling constant belonged to the Z iso-
mer, which was also the major isomer. Phenoxyamine analogues 45d and 44e formed 
in approximately 1:1 isomeric ratio. Prototropic tautomerism and hindered rotation 
about the C4ʹ-C2 bond adjoining the imidazole rings251,252 broadened the 13C and 1H 
NMR signals of the imidazole rings in most of the products (Figure 15). Some imidaz-
ole ring carbon signals were weak or even missing in several samples. The chemical 
shifts of those signals were assigned from the 2D spectra. In addition, signals referring 
to the morpholino group and methine and methylene bridges connecting the outer im-
idazole ring to the second diversity group were broadened.  
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Figure 13. Some examples of HPLC traces of crude products cleaved from the resin 
(RP HPLC, 0–100% MeCN, 0.1% TFA, λ = 220 nm). 
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Figure 14. Decoupled (lower) and nondecoupled (upper) 13C spectra of the E/Z iso-
mers of oxyimino carbons of 44d. The 1JCH coupling constants 173 Hz (δ = 137.8 ppm) 
and 181 Hz (δ = 133.9 ppm) show that the major isomer has Z conformation. 
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3.4 7‐Substituted	3‐β‐D‐Ribofuranosyl‐3H‐imidazo[2,1‐i]purines	(V)	
While in the two earlier studies some well-known synthetic transformations were 
adapted to a solid-support, in this last study the situation was reversed. The reactions 
optimized for the solid-phase synthesis were utilized in solution-phase production of 7-
substituted 3-β-D-ribofuranosyl-3H-imidazo[2,1-i]purines. The swap of the reaction 
environment brought up some unexpected difficulties. The bridging of N1 and N6 of 
adenine with bromomalonaldehyde had already been successfully used both in solid- 
and solution-phase synthesis. When we tried to apply the same chemistry to unprotect-
ed adenosine, the result was a thick dark product mixture that was difficult to purify. 
Therefore, the 2' and 3' hydroxyl groups of the ribose moiety were protected with an 
isopropylidene group which seemed to have suitable stability characteristics. The 
bridging reaction was cleaner with 2',3'-O-isopropylideneadenosine (46, Scheme 16) 
and 81% yield was collected. Another advantage of the protecting group was that the 
solubility of the synthesis intermediates was enhanced, which facilitated the silica gel 
chromatographic purifications. Cleavage of the protection at the end of the syntheses 
turned out be challenging as will be shown below. Another reaction that needed read-
justments was the reductive amination of the formyl group. The required conditions for 
successful transformation on a solid-support were too harsh for solution-phase synthe-
sis. Thus, attempted reductive amination with piperidine, sodium cyanoborohydride 
and 1% formic acid in THF was found to give reduced starting material as the main 
product. Although a weaker acid catalyst, acetic acid, provided better yields, some 
reduction of the formyl group was still apparent. Although compound 50 was synthe-
sized by this procedure, cleaner products were generally obtained by using sodium 
triacetoxyborohydride in 1,2-dichloroethane. Having acceptable reaction conditions 
established, the formyl group in 47 was reductively aminated, either with piperidine 
(48a), morpholine (49a), benzylamine (50) or tert-butyl 4-aminobutanoate (52). The 
secondary amine of compound 50 was acetylated with acetic anhydride in pyridine. 
During the reaction, the 5ʹ-hydroxyl function was esterified as well. This extra acetyl 
group was selectively removed by sodium methoxide treatment yielding, after acido-
lytic deprotection, the desired nucleoside 51. The other compound containing second-
ary amine group, 52, was either lactamized after selective removal of the tert-butyl 
with 50% TFA in DCM, or alkylated reductively with benzaldehyde. The benzylation 
of secondary amine group of 52 with benzaldehyde and NaBH(OAc)3 or NaCNBH3 in 
1,2-dichloroethane was found to be very slow and addition of acetic or formic acid 
brought about formation of acylated and lactamized side products.243 Much improved 
selectivity and excellent yield was, however, obtained by using zinc-modified 
NaCNBH3 as the reducing agent.
253 
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Scheme 16. Reagents and conditions: i) BrCH(CHO)2, HCO2H, 2,6-lutidine, DMF, ii) 
piperidine (for 48a), morpholine (for 49a), NaBH(OAc)3, AcOH, DCE, iii) Cl
− 
+H3N(CH2)3CO2tBu, NaBH(OAc)3, DCE, iv) BnNH2, NaCNBH3, AcOH, THF, v) 
FeCl3·6 H2O, MeOH, DCM, vi) 0.1 mol/L aq. HCl/THF, vii) 1. Ac2O, Pyridine 2. Na-
OMe, MeOH, viii) 1. 1:1 TFA/ DCM, 2. HBTU, DIEA, DMF, ix) PhCHO, ZnCl2, 
NaCNBH3, MeOH. 
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The last step of all the syntheses, the removal of the 2',3'-O-isopropylidene protection, 
turned out to be problematic, because the compounds contained relatively acid labile 
moieties and the protecting group was unexpectedly stable. Of the methods attempted, 
80% AcOH, 25 °C254, I2/MeOH
255, PdCl2(CH3CN)2
256, ceric ammonium nitrate257, ceric 
ammonium nitrate on silica258, and hydrolysis at pH 2 were found to be too inefficient 
while harsher treatments such as 80% aqueous AcOH at reflux254 or a 1:1 mixture of 1 
mol/L aq. HCl and THF259, resulted in side reactions such as depurination or even py-
rimidine ring opening. The best results were obtained using a 1:1 mixture of 0.1 mol/L 
aq. HCl (aq.) and THF at 55 °C or FeCl3·6H2O in a 1:19 mixture of MeOH and DCM 
at elevated temperature260. The Brønsted acid-catalysed reaction was still accompanied 
by some depurination, while the cleaner Lewis acid-catalysed reaction was hampered 
by a more laborious work up that ultimately resulted in reduced yields. Because the 
methods were approximately equally yielding, the more convenient and faster former 
method was mainly used.  
3.5 Rough	Computational	Evaluation	of	Bioactivity	of	the	Compounds	
The last three papers, included in this thesis, focused on creating scaffolds useful for 
drug discovery. At this stage of the development, obeying the rules of thumb of drug-
likeness was considered less important. The applied chemistry merely displays some of 
the possibilities that the chosen scaffolds give. Nevertheless, some calculations of the 
potential bioactivity of the synthesized compounds were performed with free online 
services. GPCR ligand, ion channel modulator, kinase inhibitor, nuclear receptor lig-
and, protease inhibitor, and enzyme inhibitor likeness were predicted with Molinspira-
tion bioactivity scores calculation service v2011.06.261 The service uses a fragment-
based model which is developed by comparing active and inactive sets of molecules 
using Bayesian statistics. The results collected for the synthesized sample libraries are 
in Table 6. It can be seen that the 3H-imidazo[2,1-i]purines (28, 32) which are small, 
structurally simple and quite planar molecules gather generally higher scores than the 
2,4ʹ-biimidazoles (43–45). The 3H-imidazo[2,1-i]purines have relatively high scores in 
GPCR ligand, kinase inhibitor, and enzyme inhibitor likeness while they are predicted 
not to bind well in nuclear receptors or proteases. The synthesized 2,4ʹ-biimidazoles, 
which are larger and contain more polar atoms, show lower overall scores in this 
screen, as could be expected. Especially they seem to be poor ion channel blockers and 
nuclear receptor ligands. The lower overall scores can mean that they are possibly 
more selective, if a suitable target is found. Finally, the 3-β-D-ribofuranosyl-3H-
imidazo[2,1-i]purines (48–55), while having a relatively large polar surface area alike, 
are predicted to be good GPCR ligands or enzyme inhibitors. The scores predict also 
functionality as ion channel blockers or kinase inhibitors. 
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Table 6. Molinspiration bioactivity scores of the synthesized sample compounds. Dark 

















28 0.48 -0.01 0.13 -0.33 0.32 0.30 
32a 0.41 0.29 0.73 -0.83 -0.22 0.50 
32b 0.44 0.28 0.62 -0.77 -0.11 0.48 
32c 0.45 0.40 0.55 -1.22 -0.29 0.54 
32d 0.50 0.34 0.49 -0.64 0.17 0.53 
32d – t-Bu 0.49 0.39 0.48 -0.90 -0.03 0.67 
32e 0.43 0.24 0.56 -1.13 -0.18 0.42 
32f 0.51 0.19 0.65 -0.87 -0.02 0.53 
32g 0.43 0.34 0.57 -1.08 -0.37 0.47 
32h 0.53 0.36 0.58 -0.90 -0.12 0.46 
32i 0.54 0.40 0.63 -0.92 -0.20 0.53 
32j 0.67 0.43 0.59 -0.67 0.10 0.71 
32k 0.59 0.40 0.55 -0.49 0.24 0.58 
32l 0.69 0.36 0.56 -0.51 0.06 0.59 
32m 0.67 0.34 0.63 -0.46 0.12 0.59 
32n 0.67 0.35 0.53 -0.35 0.21 0.59 
32o 0.67 0.27 0.53 -0.54 0.18 0.54 
32p 0.50 -0.11 0.12 -0.42 0.43 0.29 
32p – Fmoc 0.75 0.40 0.61 -0.59 0.35 0.64 
32q 0.47 0.22 0.40 -1.05 -0.11 0.40 
















42a 0.58 0.05 0.32 -0.04 0.67 0.67 
42b 0.40 -0.12 0.15 -0.47 0.29 0.37 
43a 0.41 -0.08 0.21 -0.01 0.48 0.43 
43b -0.16 -1.06 -0.68 -1.01 -0.02 -0.35 
43c 0.42 0.00 0.19 -0.13 0.47 0.38 
43d 0.44 -0.09 0.24 -0.04 0.44 0.45 
43e 0.23 -0.37 -0.08 -0.48 0.23 0.20 
43f 0.45 0.00 0.22 -0.16 0.44 0.40 
43g 0.46 -0.32 0.23 -0.15 0.39 0.29 
43h 0.43 -0.10 0.32 -0.09 0.44 0.48 
















43i 0.45 0.07 0.30 -0.20 0.44 0.45 
44a 0.48 0.18 0.23 -0.12 0.51 0.45 
44b 0.51 0.17 0.25 -0.15 0.47 0.48 
44c 0.54 -0.02 0.37 -0.02 0.42 0.46 
44d 0.50 -0.07 0.37 -0.08 0.48 0.56 
44e 0.44 -0.02 0.24 -0.14 0.48 0.49 
45a 0.01 -0.76 -0.44 -0.71 0.06 -0.10 
45b 0.46 -0.13 0.22 -0.08 0.51 0.47 
45c 0.24 -0.28 -0.08 -0.39 0.23 0.27 
45d 0.36 -0.52 -0.01 -0.28 0.41 0.15 
45e 0.48 -0.21 0.18 -0.20 0.41 0.28 


















48b 0.97 0.52 0.64 -0.76 0.16 0.86 
49b 0.90 0.45 0.67 -0.80 0.12 0.82 
51 0.77 0.27 0.43 -0.73 0.11 0.67 
53 0.93 0.40 0.48 -0.85 0.22 0.77 
55 0.73 0.19 0.33 -0.49 0.21 0.60 
55 – t-Bu 0.82 0.38 0.44 -0.50 0.18 0.73 
 
Potential protein targets for the compounds were searched from DrugBank262 (4645 
chemical structures), Binding database263 (364221 structures), and PDB264 (7072 struc-
tures) with ChemMapper265266,267 using a similarity threshold of 1.2 (60% similarity). 
ChemMapper is a free web service which integrates pharmacophore matching and 
volumetric similarity approaches to find compounds with high 3D similarity to known 
active compounds with available pharmacology annotation. The probability of interac-
tion is then calculated for the query structures with proteins that associated with the 
highest scoring database compounds. With exception of molecules from PDB, Chem-
Mapper uses several low-energy conformations for the database compounds for the 3D 
similarity calculation. While this increases coverage and accuracy, having only one 
conformer of the query molecule limits it a lot. For the screening, the energies of 3D 
conformations of the compounds were first minimized with MM2 calculations and 
MOPAC2009268 (PM6 method) using Chem3D Pro version 13.0.0.3015269. Because 
ChemMapper uses only one conformation of the query molecule in target navigator 
mode, both imidazole tautomers of the 2,4ʹ-biimidazoles (43–45) were calculated. Both 
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Z and E isomers of the phenoxyaminated compounds were used in the screening, while 
only Z isomers of the methoxyaminated compounds were screened.  
Majority of the 3H-imidazo[2,1-i]purines (32) returned hits (Table 7) and generally the 
number of targets per compound was high in the screened databases while only few 
2,4ʹ-biimidazoles (43–45) and 3-β-D-ribofuranosyl-3H-imidazo[2,1-i]purines (48–55) 
returned hits. The most popular targets for 32 include human EGFR tyrosine kinase, 
dihydrofolate reductase, sodium channel protein type 5 subunit α, inducible nitric ox-
ide synthase, adenosine receptors A1 and A2A, and cyclin-dependent kinase 2. 3-
Methyladenine DNA glycosylase (MAGIII) of Helicobacter pylori gathered several 
high scoring hits in PDB because it binds 3H-imidazo[2,1-i]purine which is the parent 
structure of the first library. Aurora kinase A and cyclin-dependent kinase 2 were the 
most frequently encountered targets for compounds 42–45. Compounds 49b and 53 
were the only hitters in the last group. Their targets include for example adenosine 
receptor A1 and metabotropic glutamate receptor 1 which belong to G-protein coupled 
receptors. 
Table 7. Number of compounds with hits in databases screened with ChemMapper. 
Compound DrugBank Binding database PDB 
28,32 11 16 19 
42–45 2 6 2 





The beginning of the Results and Discussion chapter focused on development and ap-
plication of methods for solid-phase peptide synthesis. While four homodetic bicyclic 
peptides were successfully synthesized on a solid support, the approach described in 
the second work turned out to have limited value for the intended use. Because of the 
difficulties encountered in the syntheses and changes in the project funding, this pro-
ject was not continued further. 
For the synthetic part, the aims of the thesis were met. Unfortunately, most of the com-
pounds were not tested or used for the intended purpose. Some of the compounds were 
screened by a local pharmaceutical company against targets unknown to the author. 
The possible biological activity of the compounds from the last three papers was 
roughly evaluated by using free online virtual screening services. As could be ex-
pected, the compounds 32 which follow better the rules of drug-likeness got higher 
bioactivity scores than compounds from the papers IV and V. More targets for 32 were 
also found in molecular shape superposition and chemical feature matching of Chem-
Mapper. This does not mean that they are better candidates but merely that their struc-
ture resembles more closely the ligand structures contained in the databases screened. 
It is known that the chemical space that combinatorial libraries cover is small.3 There-
fore, one of our aims was to develop scaffolds that would widen that space. The types 
of virtual screening that was executed cannot efficiently find hits for such compounds, 




In the first work, an orthogonally protected N-Alloc-N′-Fmoc-N″-Boc-α,α-bis(amino-
methyl)-β-alanine branching unit (1) was synthesized. The scaffold is spatially small 
and lends itself for synthesis of molecules with three or four different moieties that are 
connected through carboxylic acid or amine functions. The usefulness of the scaffold 
was demonstrated by SPS of glycoclusters having three different fully acetylated gly-
copyranosyl groups (I) and by SPS of bicyclic peptides having three parallel peptide 
chains (II). Four homodetic bicyclic peptides were successfully synthesized on a solid 
support. Peptide chemistry methods were used to aid the solid-supported synthesis and 
to bring diversity to the synthesized libraries of N,N-disubstituted  (3H-imidazo[2,1-
i]purin-7-yl)methylamines (III) and 5,1ʹ,5ʹ-trisubstituted 2,4ʹ-biimidazoles (IV) as 
well. In addition to reactions familiar from the peptide chemistry, some other reactions 
commonly used on a solid support, namely oximation, hydrazine formation and reduc-
tive amination, were utilized. The libraries were built on a 7-formyl-3H-imidazo[2,1-
i]purine scaffold which was constructed either in solution or on a solid support. 2ʹ-
Deoxyadenosine phosphoramidite reagent was introduced as a convenient quasi-
traceless acid-labile linker. It was used to produce a library of N,N-disubstituted  (3H-
imidazo[2,1-i]purin-7-yl)methylamines. N3-linked derivatives of similar compounds 
can be prepared by the alternative method that was used to synthesize compound N-
{[7-(N-benzylacetamidomethyl)imidazo[2,1-i]purin-3-yl]acetyl}phenylalanine (28). In 
the fourth paper a small library of 5,1ʹ,5ʹ-trisubstituted 2,4ʹ-biimidazoles was synthe-
sized on amino acid functionalized solid supports. The method is applicable for pro-
duction of larger libraries by increasing the selection of the diversity reagents used, 
namely the resin, O-substituted hydroxylamine, amine and acid halide. Finally the 
method to produce 7-substituted 3H-imidazo[2,1-i]purines on solid support was suc-
cessfully adapted to solution chemistry to produce 7-substituted 3-β-D-ribofuranosyl-




The synthetic and characterization methods used are described in the original publica-
tions (I-V) appended to this thesis. An exception is the intervening pyrimidine ring 
opening of 7-formyl 3H-imidazo[2,1-i]purine (33) on a solid support by base or acid 
catalysed hydrolyses which are described below. Outcome of the reactions described 
below was analysed by HPLC-MS method described in IV supporting information. 
Base catalysed hydrolysis of 2-(7-formyl-3H-imidazo[2,1-i]purin-3-yl)acetic acid 
on a solid-support. Aminomethyl NovaGel resin (0.100 g, 0.77 mmol/g) was preswol-
len with DMF (200 µL). Fmoc Rink linker (124.6 mg, 0.231 mmol), TBTU (74.2 mg, 
0.231 mmol) and DIEA (48.5 µL, 0.277 mmol) were dissolved in DMF (500 µL) and 
after 5 minutes activation added to the resin. The reaction mixture was shaken for 5 
hours, filtered, washed successively with DMF, DMF/MeOH, MeOH, DMF, DCM, 
DCM/MeOH, MeOH, and Et2O and then dried in a vacuum desiccator. The resin sub-
stitution was according to Fmoc loading assay 0.50 mmol/g. The Fmoc Rink amide 
NovaGel resin was then capped with a 30 min treatment with a solution of acetic anhy-
dride (100 L), 2,6-lutidine (100 L), and N-methylimidazole (160 L) in THF (1.64 
mL). The resin was washed with THF, THF/MeOH, THF, DCM, MeOH, and Et2O and 
then dried in a vacuum desiccator. Fmoc protection was removed from the resin with 
20% piperidine in DMF in 20 minutes. Resin was successively washed with DMF, 
DCM, MeOH, and Et2O and dried in vacuum. Fmoc-valine (78.4 mg, 0.231 mmol) was 
coupled to the resin as described for Fmoc Rink linker except that the reaction was 
repeated (Fmoc loading 0.540 mmol/g). Fmoc protection was removed from the resin 
as before. Compound 36c (56.6 mg, 0.231 mmol), TBTU (74.2 mg, 0.231 mmol), 
DIEA (48.5 µL, 0.277 mmol) and DMF (1000 µL) were mixed and added onto the 
deprotected resin. The reaction suspension was kept in 80 °C for 3 hours and shaken at 
room temperature overnight. According to ninhydrin test, there were free amino groups 
left in the support. One equivalent of DIEA was added (40 µL, 0.231 mmol) and the 
reaction mixture was heated at 55 °C for a day and at room temperature overnight. The 
apparent amount of precipitate had decreased and the ninhydrin test was clear. The 
mixture was filtered and washed with DMF, DMF/MeOH, DMSO, DMSO/MeOH, 
MeOH, DMF, DMF/water, DMF, DCM, MeOH, THF, MeOH, and Et2O and dried in a 
vacuum desiccator. Washing with DIEA/DMF mixture would have been beneficial for 
washing process. The dried resin was swollen in THF, filtered and a mixture of THF 
(250 µL) and 0.16 mol/L aqueous NaOH (250 µL) was added. The reaction mixture 
was agitated for 3 hours 30 minutes at 55 °C and at room temperature overnight. The 




Acid catalysed hydrolysis of 2-(7-formyl-3H-imidazo[2,1-i]purin-3-yl)acetic acid 
on a solid-support. HMBA-AM resin (125 mg, 0.80 mmol/g) was swollen in DMF. 
Fmoc-valine (339.4 mg, 1.00 mmol) was dissolved in dry DCM with the aid of few 
drops of DMF. DIC (80 µL, 0.50 mmol) was added to the solution and the mixture 
stirred for 20 minutes in a closed flask. DCM was evaporated with a rotary evaporator. 
The residue was dissolved in DMF and added to the swollen resin. Likewise dissolved 
dimethylaminopyridine (1.2 mg, 0.01 mmol) was added and the reaction mixture was 
shaken for 6 hours. The resin was filtered and washed with DMF, DCM, DCM/MeOH, 
and MeOH, and dried in a vacuum desiccator yielding Fmoc-Val-HMBA resin (load-
ing 0.623 mmol/g). The resin was then capped with acetic anhydride and Fmoc protec-
tions removed (see above). Compound 36c (73.6 mg, 0.300 mmol) and DIEA (104.5 
µL, 0.600 mmol) were dissolved in DMF (1000 µL) and added onto the deprotected 
resin. HATU (114.1 mg, 0.300 mmol) was suspended in DMF (200 µL) and added 
onto the mixture. The reaction was shaken 24 hours, filtered and washed with DMF, 
DMF/MeOH, DMF, water, pyridine, DMF, DIEA/DMF, DMF, DCM, DCM/MeOH, 
MeOH, AcOH, DCM, MeOH and dried in vacuum. The resin was capped as before. 
For the pyrimidine ring hydrolysis, the resin was shaken 18 hours in a mixture of 4 
mol/L HCl in dioxane (1.80 mL) and water (0.20 mL). The dioxane solution turned to 
yellowish green during the reaction and the solid support dark green. The resin was 
filtered and washed with dioxane, water/dioxane, water, dioxane, MeOH, DCM, 2% 
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